stat5 p y694 Search Results


anti-phospho-stat5 (p-stat5) alexa 488  (Becton Dickinson)
90
Becton Dickinson anti-phospho-stat5 (p-stat5) alexa 488
Flow cytometric gating strategy adopted to identify CD33+/CD34+ precursor cells. A representative JMML patient is showed. Mononuclear cells were initially gated to exclude debris and residual granulocytes by physical parameters ( a ); all myeloid cells were selected by their reactivity to anti-CD33 antibody ( b ); myeloid precursors were then identified as CD33+/CD34+ double positive cells ( c ). CD33+/CD34+ cells were further checked for their negativity to anti-CD14 antibody ( d ) and low expression of CD45 ( e ), as features of myeloid precursor cells. <t>p-STAT5</t> response was then measured on these selected cells by dual SSC/STAT5 cytogram ( f ). In panel ( e ), only CD33+/CD34+/CD14− gated cells are shown. In panel ( f ), only CD33+/CD34+/CD14−/CD45low gated cells are shown.
Anti Phospho Stat5 (P Stat5) Alexa 488, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-phospho-stat5 (p-stat5) alexa 488/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
anti-phospho-stat5 (p-stat5) alexa 488 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
stat5 antibody  (Cell Signaling Technology Inc)
90
Cell Signaling Technology Inc stat5 antibody
Flow cytometric gating strategy adopted to identify CD33+/CD34+ precursor cells. A representative JMML patient is showed. Mononuclear cells were initially gated to exclude debris and residual granulocytes by physical parameters ( a ); all myeloid cells were selected by their reactivity to anti-CD33 antibody ( b ); myeloid precursors were then identified as CD33+/CD34+ double positive cells ( c ). CD33+/CD34+ cells were further checked for their negativity to anti-CD14 antibody ( d ) and low expression of CD45 ( e ), as features of myeloid precursor cells. <t>p-STAT5</t> response was then measured on these selected cells by dual SSC/STAT5 cytogram ( f ). In panel ( e ), only CD33+/CD34+/CD14− gated cells are shown. In panel ( f ), only CD33+/CD34+/CD14−/CD45low gated cells are shown.
Stat5 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/stat5 antibody/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
stat5 antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
antibodies targeting c-abl, ship1, p-stat5 (y694), stat5, p-akt (s473), akt and p-crkl (y207)  (Cell Signaling Technology Inc)
90
Cell Signaling Technology Inc antibodies targeting c-abl, ship1, p-stat5 (y694), stat5, p-akt (s473), akt and p-crkl (y207)
Flow cytometric gating strategy adopted to identify CD33+/CD34+ precursor cells. A representative JMML patient is showed. Mononuclear cells were initially gated to exclude debris and residual granulocytes by physical parameters ( a ); all myeloid cells were selected by their reactivity to anti-CD33 antibody ( b ); myeloid precursors were then identified as CD33+/CD34+ double positive cells ( c ). CD33+/CD34+ cells were further checked for their negativity to anti-CD14 antibody ( d ) and low expression of CD45 ( e ), as features of myeloid precursor cells. <t>p-STAT5</t> response was then measured on these selected cells by dual SSC/STAT5 cytogram ( f ). In panel ( e ), only CD33+/CD34+/CD14− gated cells are shown. In panel ( f ), only CD33+/CD34+/CD14−/CD45low gated cells are shown.
Antibodies Targeting C Abl, Ship1, P Stat5 (Y694), Stat5, P Akt (S473), Akt And P Crkl (Y207), supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies targeting c-abl, ship1, p-stat5 (y694), stat5, p-akt (s473), akt and p-crkl (y207)/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
antibodies targeting c-abl, ship1, p-stat5 (y694), stat5, p-akt (s473), akt and p-crkl (y207) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
phosphorylated stat5  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc phosphorylated stat5
( a ) IL-2 stimulation of the JAK–STAT pathway. ( b ) Single-cell pSTAT5 abundance in response to JAK inhibitor AZD1480. Inset, the coefficient of variation (CV) response to inhibition. ( c ) Single-cell contour plot of total <t>STAT5</t> abundance and pSTAT5 in cells not treated with inhibitor, [I JAK ]=0. Curve shows the resulting geometric mean of the pSTAT5 abundance conditioned on STAT5 abundance per cell. ( d ) Cell-to-Cell variability analysis reveals that the pSTAT5 response amplitude is correlated with STAT5 abundance. In addition, the sensitivity of cells to inhibition (IC 50 ) exhibits a small negative correlation with STAT5 abundance (errorbars are standard deviation of experimental duplicates).
Phosphorylated Stat5, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phosphorylated stat5/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
phosphorylated stat5 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
p(y641)-stat6  (Cell Signaling Technology Inc)
90
Cell Signaling Technology Inc p(y641)-stat6
( a ) IL-2 stimulation of the JAK–STAT pathway. ( b ) Single-cell pSTAT5 abundance in response to JAK inhibitor AZD1480. Inset, the coefficient of variation (CV) response to inhibition. ( c ) Single-cell contour plot of total <t>STAT5</t> abundance and pSTAT5 in cells not treated with inhibitor, [I JAK ]=0. Curve shows the resulting geometric mean of the pSTAT5 abundance conditioned on STAT5 abundance per cell. ( d ) Cell-to-Cell variability analysis reveals that the pSTAT5 response amplitude is correlated with STAT5 abundance. In addition, the sensitivity of cells to inhibition (IC 50 ) exhibits a small negative correlation with STAT5 abundance (errorbars are standard deviation of experimental duplicates).
P(Y641) Stat6, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p(y641)-stat6/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
p(y641)-stat6 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
p-stat5 (y694  (ABclonal Biotechnology)
90
ABclonal Biotechnology p-stat5 (y694
( a ) IL-2 stimulation of the JAK–STAT pathway. ( b ) Single-cell pSTAT5 abundance in response to JAK inhibitor AZD1480. Inset, the coefficient of variation (CV) response to inhibition. ( c ) Single-cell contour plot of total <t>STAT5</t> abundance and pSTAT5 in cells not treated with inhibitor, [I JAK ]=0. Curve shows the resulting geometric mean of the pSTAT5 abundance conditioned on STAT5 abundance per cell. ( d ) Cell-to-Cell variability analysis reveals that the pSTAT5 response amplitude is correlated with STAT5 abundance. In addition, the sensitivity of cells to inhibition (IC 50 ) exhibits a small negative correlation with STAT5 abundance (errorbars are standard deviation of experimental duplicates).
P Stat5 (Y694, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p-stat5 (y694/product/ABclonal Biotechnology
Average 90 stars, based on 1 article reviews
p-stat5 (y694 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anti-stat5 (phospho-y694) stat5a antibody  (Boster Bio)
N/A
Boster Bio Anti-Stat5 (Phospho-Y694) STAT5A Antibody catalog # A01087Y694-1. Tested in WB,IHC applications. This antibody reacts with Human,Mouse.
   Buy from Supplier

Image Search Results


Flow cytometric gating strategy adopted to identify CD33+/CD34+ precursor cells. A representative JMML patient is showed. Mononuclear cells were initially gated to exclude debris and residual granulocytes by physical parameters ( a ); all myeloid cells were selected by their reactivity to anti-CD33 antibody ( b ); myeloid precursors were then identified as CD33+/CD34+ double positive cells ( c ). CD33+/CD34+ cells were further checked for their negativity to anti-CD14 antibody ( d ) and low expression of CD45 ( e ), as features of myeloid precursor cells. p-STAT5 response was then measured on these selected cells by dual SSC/STAT5 cytogram ( f ). In panel ( e ), only CD33+/CD34+/CD14− gated cells are shown. In panel ( f ), only CD33+/CD34+/CD14−/CD45low gated cells are shown.

Journal: Blood Cancer Journal

Article Title: Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemia

doi: 10.1038/bcj.2013.56

Figure Lengend Snippet: Flow cytometric gating strategy adopted to identify CD33+/CD34+ precursor cells. A representative JMML patient is showed. Mononuclear cells were initially gated to exclude debris and residual granulocytes by physical parameters ( a ); all myeloid cells were selected by their reactivity to anti-CD33 antibody ( b ); myeloid precursors were then identified as CD33+/CD34+ double positive cells ( c ). CD33+/CD34+ cells were further checked for their negativity to anti-CD14 antibody ( d ) and low expression of CD45 ( e ), as features of myeloid precursor cells. p-STAT5 response was then measured on these selected cells by dual SSC/STAT5 cytogram ( f ). In panel ( e ), only CD33+/CD34+/CD14− gated cells are shown. In panel ( f ), only CD33+/CD34+/CD14−/CD45low gated cells are shown.

Article Snippet: Samples were incubated with anti-phospho-STAT5 (p-STAT5) Alexa 488 (Y694, clone 47, BD Biosciences) or isotype IgG 1 k Alexa 488 (clone MOPC-21, BD Biosciences), anti-CD33 PE (clone P67.6, BD Biosciences), anti-CD34 APC (clone 8G12, BD Biosciences), anti-CD45 PerCP (clone 2D1, BD Biosciences) and anti-CD38 PE-Cy7 (clone HB7, BD Biosciences) antibodies.

Techniques: Expressing

Training set samples assessed the best threshold. The p-STAT5 responses were measured at each GM-CSF concentration in the training set of samples (11 JMMLs and 23 controls). The best dose to distinguish JMML from non-JMML samples was identified at 0.1 ng/ml of GM-CSF ( P <0.0001). p-STAT5-positive cells (%) were quantified by scaling the maximum % of p-STAT5+ cells at 100 and the unstimulated p-STAT5+ cells to 0.

Journal: Blood Cancer Journal

Article Title: Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemia

doi: 10.1038/bcj.2013.56

Figure Lengend Snippet: Training set samples assessed the best threshold. The p-STAT5 responses were measured at each GM-CSF concentration in the training set of samples (11 JMMLs and 23 controls). The best dose to distinguish JMML from non-JMML samples was identified at 0.1 ng/ml of GM-CSF ( P <0.0001). p-STAT5-positive cells (%) were quantified by scaling the maximum % of p-STAT5+ cells at 100 and the unstimulated p-STAT5+ cells to 0.

Article Snippet: Samples were incubated with anti-phospho-STAT5 (p-STAT5) Alexa 488 (Y694, clone 47, BD Biosciences) or isotype IgG 1 k Alexa 488 (clone MOPC-21, BD Biosciences), anti-CD33 PE (clone P67.6, BD Biosciences), anti-CD34 APC (clone 8G12, BD Biosciences), anti-CD45 PerCP (clone 2D1, BD Biosciences) and anti-CD38 PE-Cy7 (clone HB7, BD Biosciences) antibodies.

Techniques: Concentration Assay

Representative flow cytometric contour plots of p-STAT5 response in CD33+/CD34+ cells. Dual SSC/STAT5 cytograms from a JMML (upper panels) and a control (lower panels) are shown. Contour plots are referred to CD33+/CD34+ cells identified by gating strategy described in . For each dose of GM-CSF, the raw percentage of responding p-STAT5-positive cells is shown. Response to stimulation at each GM-CSF dose was then quantified by scaling the maximum percentage of p-STAT5+ cells at 100 and the unstimulated p-STAT5+ cells to 0. According to this criteria, calculated p-STAT5 responses are indicated in parenthesis for each stimulation dose.

Journal: Blood Cancer Journal

Article Title: Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemia

doi: 10.1038/bcj.2013.56

Figure Lengend Snippet: Representative flow cytometric contour plots of p-STAT5 response in CD33+/CD34+ cells. Dual SSC/STAT5 cytograms from a JMML (upper panels) and a control (lower panels) are shown. Contour plots are referred to CD33+/CD34+ cells identified by gating strategy described in . For each dose of GM-CSF, the raw percentage of responding p-STAT5-positive cells is shown. Response to stimulation at each GM-CSF dose was then quantified by scaling the maximum percentage of p-STAT5+ cells at 100 and the unstimulated p-STAT5+ cells to 0. According to this criteria, calculated p-STAT5 responses are indicated in parenthesis for each stimulation dose.

Article Snippet: Samples were incubated with anti-phospho-STAT5 (p-STAT5) Alexa 488 (Y694, clone 47, BD Biosciences) or isotype IgG 1 k Alexa 488 (clone MOPC-21, BD Biosciences), anti-CD33 PE (clone P67.6, BD Biosciences), anti-CD34 APC (clone 8G12, BD Biosciences), anti-CD45 PerCP (clone 2D1, BD Biosciences) and anti-CD38 PE-Cy7 (clone HB7, BD Biosciences) antibodies.

Techniques:

Comparison of p-STAT5-positive cells (%) induced by 0.1 ng/ml of GM-CSF in the validation series comprising 11 JMML samples (central box plot), 24 controls (left box plot) and 7 samples from patients with other diseases mimicking JMML at presentation (right box plot). The discriminating threshold (17.17% as assessed in the training set) is indicated. The bold line inside each box plot indicates the median level, while the upper and lower lines indicate the maximum and minimum observed values, respectively. There are no outliers.

Journal: Blood Cancer Journal

Article Title: Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemia

doi: 10.1038/bcj.2013.56

Figure Lengend Snippet: Comparison of p-STAT5-positive cells (%) induced by 0.1 ng/ml of GM-CSF in the validation series comprising 11 JMML samples (central box plot), 24 controls (left box plot) and 7 samples from patients with other diseases mimicking JMML at presentation (right box plot). The discriminating threshold (17.17% as assessed in the training set) is indicated. The bold line inside each box plot indicates the median level, while the upper and lower lines indicate the maximum and minimum observed values, respectively. There are no outliers.

Article Snippet: Samples were incubated with anti-phospho-STAT5 (p-STAT5) Alexa 488 (Y694, clone 47, BD Biosciences) or isotype IgG 1 k Alexa 488 (clone MOPC-21, BD Biosciences), anti-CD33 PE (clone P67.6, BD Biosciences), anti-CD34 APC (clone 8G12, BD Biosciences), anti-CD45 PerCP (clone 2D1, BD Biosciences) and anti-CD38 PE-Cy7 (clone HB7, BD Biosciences) antibodies.

Techniques:

Comparison of p-STAT5-positive cells (%) induced by 0.1 ng/ml of GM-CSF according to the different cell source. In all, 17 JMML BM samples (left box plot), 5 JMML PB samples (middle left box plot), 12 BM samples and 2 PB samples (middle right and right box plot, respectively) from patients with other diseases mimicking JMML are shown. The discriminating threshold (17.17% as assessed in the training set) is indicated. The bold line inside each box plot indicates the median level, while the upper and lower lines indicate the maximum and minimum observed values, respectively. There are no outliers.

Journal: Blood Cancer Journal

Article Title: Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemia

doi: 10.1038/bcj.2013.56

Figure Lengend Snippet: Comparison of p-STAT5-positive cells (%) induced by 0.1 ng/ml of GM-CSF according to the different cell source. In all, 17 JMML BM samples (left box plot), 5 JMML PB samples (middle left box plot), 12 BM samples and 2 PB samples (middle right and right box plot, respectively) from patients with other diseases mimicking JMML are shown. The discriminating threshold (17.17% as assessed in the training set) is indicated. The bold line inside each box plot indicates the median level, while the upper and lower lines indicate the maximum and minimum observed values, respectively. There are no outliers.

Article Snippet: Samples were incubated with anti-phospho-STAT5 (p-STAT5) Alexa 488 (Y694, clone 47, BD Biosciences) or isotype IgG 1 k Alexa 488 (clone MOPC-21, BD Biosciences), anti-CD33 PE (clone P67.6, BD Biosciences), anti-CD34 APC (clone 8G12, BD Biosciences), anti-CD45 PerCP (clone 2D1, BD Biosciences) and anti-CD38 PE-Cy7 (clone HB7, BD Biosciences) antibodies.

Techniques:

( a ) IL-2 stimulation of the JAK–STAT pathway. ( b ) Single-cell pSTAT5 abundance in response to JAK inhibitor AZD1480. Inset, the coefficient of variation (CV) response to inhibition. ( c ) Single-cell contour plot of total STAT5 abundance and pSTAT5 in cells not treated with inhibitor, [I JAK ]=0. Curve shows the resulting geometric mean of the pSTAT5 abundance conditioned on STAT5 abundance per cell. ( d ) Cell-to-Cell variability analysis reveals that the pSTAT5 response amplitude is correlated with STAT5 abundance. In addition, the sensitivity of cells to inhibition (IC 50 ) exhibits a small negative correlation with STAT5 abundance (errorbars are standard deviation of experimental duplicates).

Journal: Nature Communications

Article Title: Dichotomy of cellular inhibition by small-molecule inhibitors revealed by single-cell analysis

doi: 10.1038/ncomms12428

Figure Lengend Snippet: ( a ) IL-2 stimulation of the JAK–STAT pathway. ( b ) Single-cell pSTAT5 abundance in response to JAK inhibitor AZD1480. Inset, the coefficient of variation (CV) response to inhibition. ( c ) Single-cell contour plot of total STAT5 abundance and pSTAT5 in cells not treated with inhibitor, [I JAK ]=0. Curve shows the resulting geometric mean of the pSTAT5 abundance conditioned on STAT5 abundance per cell. ( d ) Cell-to-Cell variability analysis reveals that the pSTAT5 response amplitude is correlated with STAT5 abundance. In addition, the sensitivity of cells to inhibition (IC 50 ) exhibits a small negative correlation with STAT5 abundance (errorbars are standard deviation of experimental duplicates).

Article Snippet: Cells were labelled with primary antibodies against doubly phosphorylated ERK 1/2 (pT202, pY204; clone E10; used at 1:300 dilution), phosphorylated MEK 1/2 (p-S221; clone 166F8; used at 1:100 dilution), phosphorylated STAT5 (p-Y694; clone C11C5; used at 1:200 dilution)—purchased from Cell Signaling Technology (Beverly, Massachusetts)—and polyclonal goat anti-STAT5 (catalogue number sc-835-G; used at 1:200 dilution) purchased from Santa Cruz Biotechnology (Santa Cruz, California).

Techniques: Inhibition, Standard Deviation

( a ) Model diagrams that represent three possible mechanisms of inhibition. ( b ) Each model was tested against our data by measuring the sum of squared residuals (total residuals) between our model predictions and the data points—a lower value means better agreement between model and data. The model was fit to all the data point presented in c . ( c ) Overlay of data (circles) with the optimal model and parameter set from fit (lines). ( d ) The linearized data was derived from the optimal model and the corresponding parameters reveal agreement between model (line) and the data (open circles). ( e ) Overlay of measured IC 50 with respect to STAT5 abundance as measured from CCVA analysis of data (triangles; errorbars standard deviation experimental duplicates) and predicted by our optimal model (line).

Journal: Nature Communications

Article Title: Dichotomy of cellular inhibition by small-molecule inhibitors revealed by single-cell analysis

doi: 10.1038/ncomms12428

Figure Lengend Snippet: ( a ) Model diagrams that represent three possible mechanisms of inhibition. ( b ) Each model was tested against our data by measuring the sum of squared residuals (total residuals) between our model predictions and the data points—a lower value means better agreement between model and data. The model was fit to all the data point presented in c . ( c ) Overlay of data (circles) with the optimal model and parameter set from fit (lines). ( d ) The linearized data was derived from the optimal model and the corresponding parameters reveal agreement between model (line) and the data (open circles). ( e ) Overlay of measured IC 50 with respect to STAT5 abundance as measured from CCVA analysis of data (triangles; errorbars standard deviation experimental duplicates) and predicted by our optimal model (line).

Article Snippet: Cells were labelled with primary antibodies against doubly phosphorylated ERK 1/2 (pT202, pY204; clone E10; used at 1:300 dilution), phosphorylated MEK 1/2 (p-S221; clone 166F8; used at 1:100 dilution), phosphorylated STAT5 (p-Y694; clone C11C5; used at 1:200 dilution)—purchased from Cell Signaling Technology (Beverly, Massachusetts)—and polyclonal goat anti-STAT5 (catalogue number sc-835-G; used at 1:200 dilution) purchased from Santa Cruz Biotechnology (Santa Cruz, California).

Techniques: Inhibition, Derivative Assay, Standard Deviation